Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8316507 | 1.00 | HRH3 (0.50) | HRH3USP2CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL1691277 | 0.84 | HRH3 (0.49) | HRH3USP2CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL29930648 | 0.81 | SPR (0.42) | HRH3USP2CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL17134739 | 0.81 | BRD4 (0.42) | HRH3USP2CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL31387908 | 0.81 | HSD11B1 (0.42) | HRH3CYP2C19MAPK1ALDH1A1SIGMAR1 | |
| SCHEMBL3713549 | 0.81 | HSD11B1 (0.42) | HRH3CYP2C19MAPK1ALDH1A1SIGMAR1 | |
| SCHEMBL22499434 | 0.80 | SPR (0.43) | HRH3CYP2C19MAPK1ALDH1A1KMT2A | |
| SCHEMBL30738685 | 0.80 | MAPK1 (0.44) | USP2CYP2C19MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL29550707 | 0.77 | TSHR (0.42) | USP2CYP2C19MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL30111021 | 0.77 | ESR1 (0.46) | USP2CYP2C19MAPK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2025-01-28 | — | — | US | disclosed |
| CN-113493440-B | Salt of nitrogen-containing heteroaromatic derivative and crystal form thereof | 上海翰森生物医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-115052866-B | Crystal form of nitrogen-containing heteroaromatic derivative free alkali | 上海翰森生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115353509-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-115353509-A | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-111295374-B | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114478585-A | Nitrogen-containing fused heterocyclic compound and preparation method and application thereof | 上海青煜医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022089406-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海青煜医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| EP-3984999-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | Beijing Shenogen Pharma Group Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388977-A1 | SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR | PTPN1, PTPN5, PTPN18 | HRH3 4683/4885USP2 2268/4885CYP2C19 3302/4885 |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | PTPN1, PTPN5, PTPN18 | HRH3 4683/4885USP2 2268/4885CYP2C19 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.